In vivo bodistribution, PET imaging, and tumor accumulation of 86Y-and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice
IMMUNOGLOBULIN E ANTIBODY;
IMMUNOGLOBULIN E ANTIBODY 19G9 IN 111;
IMMUNOGLOBULIN E ANTIBODY 19G9 Y 86;
IMMUNOGLOBULIN G ANTIBODY;
IMMUNOGLOBULIN G ANTIBODY 19G9 IN 111;
IMMUNOGLOBULIN G ANTIBODY 19G9 Y 86;
IMMUNOGLOBULIN G1 ANTIBODY;
IMMUNOGLOBULIN G1 ANTIBODY 19G9 IN 111;
IMMUNOGLOBULIN G1 ANTIBODY 19G9 Y 86;
INDIUM 111;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY RG 1 19G9;
SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;
SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY 19G9 IN 111;
SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY 19G9 Y 86;
UNCLASSIFIED DRUG;
YTTRIUM 86;
CHELATING AGENT;
DRUG DERIVATIVE;
INDIUM;
ISOTHIOCYANIC ACID DERIVATIVE;
N (2 AMINO 3 (4 ISOTHIOCYANATOPHENYL)PROPYL)CYCLOHEXANE 1,2 DIAMINE N,N',N',N'',N'' PENTAACETIC ACID;
N-(2-AMINO-3-(4-ISOTHIOCYANATOPHENYL)PROPYL)CYCLOHEXANE-1,2-DIAMINE-N,N',N',N'',N''-PENTAACETIC ACID;
PENTETIC ACID;
RADIOPHARMACEUTICAL AGENT;
YTTRIUM;
The neuronal class 2 TSR proteins F-spondin and mindin: A small family with divergent biological activities
Feinstein Y, Klar A. The neuronal class 2 TSR proteins F-spondin and mindin: a small family with divergent biological activities. Int J Biochem Cell Biol. 2004;36:975-980.
Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer
Parry R, Schneider D. Hudson D, et al. Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Res. 2005;65:8397-8405.
Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts
Hu S, Shively L, Raubitschek A, et at. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 1996;56:3055-3061.
Obligate multivalent recognition of cell surface tomoregulin following selection from a multivalent phage antibody library
Heitner T. Satozawa N, McLean K, et al. Obligate multivalent recognition of cell surface tomoregulin following selection from a multivalent phage antibody library. J Biomol Screen. 2006;11:985-995.
High levels of protein expression using different mammalian CMV promoters in several cell lines
Xia W, Bringmann P, McClary J, et al. High levels of protein expression using different mammalian CMV promoters in several cell lines. Protein Expr Purif. 2006;45:115-124.
A rapid single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies
Nikula TK. Curcio MJ, Brechbiel MW, Gansow OA, Finn RD, Scheinberg DA. A rapid single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol. 1995;22:387-390.
Performance evaluation of the microPET focus: A third-generation microPET scanner dedicated to animal imaging
Tai YC, Ruangraa A, Rowland DJ, et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med. 2005;46:455-463.
Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin
Borsi L, Balza E, Bestagno M, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer. 2002;102:75-85.
Shields RL, Namenuk AK, Hong K. et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIIl, and FcRn and design of IgGl variants with improved binding t0 the FcγR. J Biol Client. 2001 ;276:6591-6604.
Shields RL, Namenuk AK, Hong K. et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIIl, and FcRn and design of IgGl variants with improved binding t0 the FcγR. J Biol Client. 2001 ;276:6591-6604.
16
0035865063
Engineered antibodies with increased activity to recruit complement
Idusogie EE, Wong PY, Presta LG, et al. Engineered antibodies with increased activity to recruit complement. J Immunol. 2001;166:2571-2575.
Enhanced half-life of genetically engineered human IgGl antibodies in a humanized FcRn mouse model: Potential application in humorally mediated autoimmune disease
Petkova SB, Akilesh S, Sproule TJ, et al. Enhanced half-life of genetically engineered human IgGl antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol. 2006;18:1759-1769.
Tunable pharmacokinetics: Modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment
Olafsen T, Kenanova VE, Wu AM. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protocols. 2006; 1:2048-2060.
Monoclonal antibody clearance: Impact of modulating the interaction of IgG with the neonatal Fc receptor
Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Wroblewski VJ. Monoclonal antibody clearance: impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem. 2007;282:1709-1717.
Rational cytokine design for increased lifetime and enhanced potency using pH- activated histidine switching
Sarkar CA, Lowenhaupt K, Horan T. Boone TC, Tidor B, Lauffenburger DA. Rational cytokine design for increased lifetime and enhanced potency using pH- activated "histidine switching." Nat Bioteclmol. 2002;20:908-913.
Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers
Adams GP, Tai MS. McCartney JE, et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res. 2006;12:1599-1605.
